TipRanks
Advertisement
Advertisement
Pacira upgraded to Neutral from Underweight at JPMorgan
PremiumThe FlyPacira upgraded to Neutral from Underweight at JPMorgan
4d ago
Pacira downgraded to Hold from Buy at Needham
Premium
The Fly
Pacira downgraded to Hold from Buy at Needham
4d ago
Pacira to be acquired by Viatris in cash deal
Premium
Company Announcements
Pacira to be acquired by Viatris in cash deal
4d ago
Pacira, Molteni Farmaceutici to expand postsurgical pain management access
PremiumThe FlyPacira, Molteni Farmaceutici to expand postsurgical pain management access
7d ago
Pacira initiated with an Outperform at Oppenheimer
Premium
The Fly
Pacira initiated with an Outperform at Oppenheimer
19d ago
Pacira initiated with a Market Perform at Leerink amid ‘formulary inertia’
Premium
The Fly
Pacira initiated with a Market Perform at Leerink amid ‘formulary inertia’
1M ago
Pacira price target raised to $25 from $24 at RBC Capital
PremiumThe FlyPacira price target raised to $25 from $24 at RBC Capital
2M ago
Pacira cuts FY26 revenue view to $735M-$760M from $745M-$770M,
Premium
The Fly
Pacira cuts FY26 revenue view to $735M-$760M from $745M-$770M,
2M ago
Pacira reports Q2 EPS 73c, consensus 65c
Premium
The Fly
Pacira reports Q2 EPS 73c, consensus 65c
2M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―